United States securities and exchange commission logo





                          April 8, 2024

       Oren Gilad, Ph.D.
       President and Chief Executive Officer
       Aprea Therapeutics, Inc.
       3805 Old Easton Road
       Doylestown, PA 18902

                                                        Re: Aprea Therapeutics,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed April 3, 2024
                                                            File No. 333-278485

       Dear Oren Gilad:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Chris
Edwards at 202-551-6761 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Fahd M.T. Riaz, Esq.